Risk of fatal pulmonary events in patients with advanced non-small-cell lung cancer treated with EGF receptor tyrosine kinase inhibitors: a comparative meta-analysis

被引：19

作者：

Abdel-Rahman, Omar ^{[1
]}

Elhalawani, Hesham ^{[1
]}

机构：

[1] Ain Shams Univ, Fac Med, Dept Clin Oncol, Cairo, Egypt

来源：

FUTURE ONCOLOGY | 2015年 / 11卷 / 07期

关键词：

afatinib; erlotinib; gefitinib; interstitial lung disease; NSCLC; RANDOMIZED PHASE-II; GROWTH-FACTOR RECEPTOR; HIGH-RESOLUTION CT; 1ST-LINE TREATMENT; DOUBLE-BLIND; JAPANESE PATIENTS; STANDARD CHEMOTHERAPY; 2ND-LINE TREATMENT; ELDERLY-PATIENTS; OPEN-LABEL;

D O I：

10.2217/fon.15.16

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We performed a meta-analysis of fatal pulmonary events associated with erlotinib, gefitinib or afatinib in patients with non-small-cell lung cancer (NSCLC). Eligible studies included randomized trials of patients with NSCLC on the three drugs describing events of high-grade pulmonary events. The relative risk of high-grade interstitial lung disease, pneumonitis, pneumonia, pulmonary embolism and hemoptysis were 4.18 (95% CI: 2.49-7.01; p < 0.00001), 1.94 (95% CI: 0.93-4.06; p = 0.08), 1.28 (95% CI: 0.92-1.77; p = 0.14), 1.6 (95% CI: 0.81-3.18 p = 0.17), 1.00 (95% CI: 0.14-7.08 p = 0.35), respectively. Our meta-analysis has demonstrated that erlotinib, gefitinib and afatinib are associated with an increased risk of high-grade interstitial lung disease in patients with NSCLC.

引用

页码：1109 / 1122

页数：14

共 61 条

[1] Risk of selected gastrointestinal toxicities in patients with advanced non-small cell lung cancer receiving erlotinib: a systematic review and meta-analysis [J].